Clinical Trials

Phase 1/2 Active not recruiting

5 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03831932 2026-05-28

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06303167 2026-05-28

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

LymphoidOther hematologic neoplasmPlasma cell

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04487080 2026-05-08

MARIPOSA

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03521154 2026-05-05

LAURA

216 enrolled 25 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03778229 2026-04-23

SAVANNAH

367 enrolled 32 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04765059 2026-04-21

COMPEL

98 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT02511106 2026-03-30

ADAURA

682 enrolled 20 charts 1 FDA

Stage IB-IIIA Non-small Cell Lung Carcinoma

NCT03433469 2026-03-30

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

27 enrolled 14 charts

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03381274 2026-03-11

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

43 enrolled 30 charts

Carcinoma, Non-Small-Cell Lung

NCT03940703 2026-02-27

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

140 enrolled 47 charts

Carcinoma, Non-Small-Cell Lung

NCT04606771 2026-02-27

CoC

30 enrolled 20 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02411448 2026-01-16

RELAY

545 enrolled 24 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04035486 2025-10-10

FLAURA2

587 enrolled 44 charts 1 FDA